Sie sind auf Seite 1von 2

International Stem Cell Corporation Receives Important Approvals Towards

Creating New Parthenogenetic Stem Cell Lines in the United State s

International Stem Cell Corporation (OTCBB:ISCO),, announced today

the achievement of a major milestone in its efforts to establish a bank of immune-matched
parthenogenetic stem cells in the United States by receiving the statutory approvals required to move
forward with the next phase of its stem cell banking program.

An independent Stem Cell Research Oversight (SCRO) committee approved ISCO's program to obtain
human oocytes (eggs) in California. The independent SCRO committee is responsible for reviewing the
scientific rationale, ethics and compliance with State and Federal regulations and guidelines for studies
involving human stem cells. This approval in combination with the earlier reported Institutional Review
Board (IRB) clearance with regard to medical safety opens the way for ISCO's stem cell banking
program to begin registering clinical investigators. ISCO's study is designed to produce new clinical-
grade human parthenogenetic stem cell lines that can be immune matched to millions of individuals
for use in the emerging field of regenerative medicine.

ISCO's breakthrough discoveries have resulted in unique stem cells carrying distinct advantages over
other humanpluripotent stem cells. ISCO uses unfertilized oocytes to create human "parthenogenetic"
stem cells (hpSCs). Like human embryonic stem cells (hESCs), hpSCs are pluripotent, i.e. they have
the capacity to become almost any cell type in the body, yet avoid ethical issues associated with use
or destruction of viable human embryos. Unlike hESCs, hpSCs can be created in a form such that they
can be immunologically matched to millions of individuals.

Currently ISCO has a collection of ten hpSC lines that are shared with collaborators and used for
research purposes. Although these ten stem cell lines conform to all relevant US standards, they were
derived outside the United States. New cell lines created under this study will be ISCO's first hpSC to
be produced in the United States. ISCO's scientists, leaders the field of creating therapeutic cells from
hpSC, will work with these lines targeting new treatments for human diseases. The company will also
share these cells with other scientists to further clinical research. ISCO intends to derive and store
these cells at its Oceanside facilities, which are designed to create cells suitable for clinical use.
Simon Craw, PhD, says, "These approvals, combined with our technology, make the establishment of
a bank of immune matched stem cells practical and allow for the possibility of cell-based therapy to be
economic for millions of people. We believe we are one of the first commercial entities in the United
States to have progressed to this point."


International Stem Cell Corporation is a California-based biotechnology company focused on the
therapeutic applications of human parthenogenetic stem cells and the development and
commercialization of cell-based research and cosmetic products. ISCO's core technology,
parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs).
hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO
scientists have created the first parthenogenic, homozygous stem cell line that can be a source of
therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of
individuals of differing sexes, ages and racial groups. This offers the potential to create the first true
stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also
produces and markets specialized cells and growth media for therapeutic research worldwide through
its subsidiary Lifeline Cell Technology and cell-based skin care products through its subsidiary Lifeline
Skin Care. More information is available at ISCO's website,
To subscribe to receive ongoing corporate communications please click on the following

Statements pertaining to anticipated technological developments and therapeutic applications, the
potential benefits of collaborations, and other opportunities for the company and its subsidiaries, along
with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that are not historical fact
(including, but not limited to statements that contain words such as "will," "should," "believes,"
"plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties, including, without limitation,
risks inherent in the development and/or commercialization of potential products and therapies,
uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future
capital, application of capital resources among competing uses, and maintenance of intellectual
property rights. Actual results may differ materially from the results anticipated in these forward-
looking statements and as such should be evaluated together with the many uncertainties that affect
the company's business, particularly those mentioned in the cautionary statements found in the
company's Securities and Exchange Commission filings. The company disclaims any intent or
obligation to update these forward-looking statements.
Key Words: Stem Cells, Biotechnology, Parthenogenesis

International Stem Cell Corporation

Kenneth C. Aldrich, Chairman
Simon Craw, PhD, Vice President